Effect of Prolonged Nightly Fasting (PNF) on Immunotherapy Treatment Outcomes in Patients with Advanced Head and Neck Cancer (HNSCC)-Role of Gut Microbiome
The purpose of this study is to determine if Prolonged nightly fast (PNF) /Time restricted eating leads to improved responses to ICB in patients with metastatic head and neck cancer.
Aim 1: Evaluate compliance to PNF in metastatic head and neck cancer patients, measured at 3 months.
This is a pilot study in preparation of a larger RCT. The RCT will be considered feasible if our pilot study has >75 % retention rate of participants through the first 3 months.
Aim 2: To evaluate dynamic changes in gut microbiome composition/diversity as well as gut microbial metabolites in patients on PNF and controls and corelate with response to ICB therapy.
Response will be measured by objective response rate (ORR) of ICB using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at 3 months
Newly diagnosed recurrent /metastatic head and neck squamous cell cancer that is not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy) and initiating standard of care immune checkpoint blocker- (Nivolumab, pembrolizumab, Atezolizumab, Avelumab or Durvalumab with or without chemotherapy), for the first time.
Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as outlined in RECIST version 1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
18 years of age or older, able to understand and voluntarily consent.
Diabetes mellitus, hyperthyroidism, pregnancy, any eating disorder including anorexia nervosa or bulimia, metabolic disorders that may affect gluconeogenesis or adaptation to short fasting periods.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, autoimmune disease requiring systemic steroids, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Patients who have known leptomeningeal metastases or untreated or symptomatic brain metastases. Treated, asymptomatic brain metastasis can be included.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub